ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2151 entries already.
A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.
Apitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will take over commercialisation cost following Phase II testing. Phase II data are due to be published in Q4/2016.
The European Patent Office’s decision to speed up examination of patent applications to 12 months without any transition period is set to ruin biotech SMEs financially and may send a blocking signal to innovators.
Roche is making up lost ground in immuno-oncology. The Swiss company’s PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy.
The new joint venture Synvina is positioned in the market for drop-in bioplastics with advanced product characteristics.
With about 38,000 attendees and 2,500 exhibitors, CPhI worldwide in Barcelona has broken another record. Personalised 3D printed pills and hypothesis generation using big data were only two trends reported.
The fate of the bioeconomy in Europe remains undecided. The evaluation of the European Commission’s bioeconomy strategy plus action plan has been delayed.
Austrian Apeiron Biologics has outlicensed the global marketing rights for its neuroblastoma antibody dinutuximab beta to British Eusa Pharma.
Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.
CAR T cell specialist bluebird bio has inked a potential US$1bn partnership with Medigene – to get access to the drug developer’s technology platform.